Skip to main content
FTREFortrea Holdings Inc.Sell4.9·$20.23

Fortrea Holdings (FTRE) Q3 2026 earnings — TrendMatrix coverage

BEAT+28.9% vs estimateEPS $0.28 vs $0.22 estCurrent verdict Sell 4.9/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
$0.28
Estimate
$0.22
Surprise
+28.9%
Revenue (period 2026-09-30)
$691.5M
Score today
4.9/10

Revenue source: xbrl.

Report record · Q3 2026

How the report landed

Fortrea Holdings (FTRE) beat the $0.22 estimate with adjusted EPS of $0.28 — a large 28.9% upside surprise.

Around the report

Coverage in the report window

  • Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $27 — benzinga, 2026-10-30
  • Truist Securities Maintains Buy on Fortrea Holdings, Raises Price Target to $29 — benzinga, 2026-10-30
  • Barclays Maintains Overweight on Fortrea Holdings, Raises Price Target to $26 — benzinga, 2026-10-30
Current read · as of 2026-11-18

Where TrendMatrix's rating stands now

TrendMatrix currently rates FTRE Sell at 4.9/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +28.9% surprise compares with a +56.0% four-quarter average. Next scheduled report: 2027-02-25.

What argues against it

  • Concentration risk — Customer: top ten customers (57.0%)
  • Concentration risk — Customer: top 20 customers (69.0%)
  • Target reached (1.6% upside)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$20.23
Price target
$20.55
Stop
$18.81
Upside to target
+1.6%
Reward-to-risk
0.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.

Healthcare context

FTRE at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$1.89B
P/E (fwd)
17.6
52-week range
$8.55–$26.16
Off 52-week high
22.7%
RSI (14)
35
Volume vs avg
0.25×
Score today
4.9/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › FTRE › Earnings › Q3 2026 earnings